Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867139 · ClinicalTrials.gov registry record · Phase 1
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
A Phase 1 study of Influenza, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 2
- Study locations
NCT00867139 is a Phase 1 study of Influenza that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 7 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00867139, a Phase 1 study of Influenza, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
Conditions Studied
Interventions
- DRUG TCAD
- DRUG Zanamivir or Oseltamivir
- OTHER Open label treatment with TCAD
Study Locations (2)
Washington
- Seattle Children's - Seattle
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867139
The ClinicalTrials.gov registry entry for NCT00867139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which TCAD is the first listed.
NCT00867139 reports 2 study locations spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00867139 about?
NCT00867139 is a clinical study titled "TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients". The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
What is the current status of trial NCT00867139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-03. Estimated completion is 2010-01.
What conditions does trial NCT00867139 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00867139?
The interventions under investigation include: TCAD (DRUG), Zanamivir or Oseltamivir (DRUG), Open label treatment with TCAD (OTHER).
Who is sponsoring clinical trial NCT00867139?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00867139 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.